U.S. Professional Services Stock News

NYSE:STAG
NYSE:STAGIndustrial REITs

Is STAG Industrial (STAG) Offering Value After Recent Share Price Weakness?

If you are wondering whether STAG Industrial is attractively priced today or whether the market has already factored in the key positives, this article walks through what the current share price might be implying about value. STAG Industrial recently closed at US$36.21, with returns of 0.6% over 7 days, an 8.9% decline over 30 days, a 1.9% decline year to date, and a 4.4% gain over the last year, which can signal shifting views on both growth potential and risk. Recent news coverage around...
NasdaqCM:PHOE
NasdaqCM:PHOEConstruction

Phoenix Asia Holdings (PHOE) Margin Compression Reinforces Bearish Narratives Despite Revenue Growth

Phoenix Asia Holdings (PHOE) has just posted its H1 2026 scorecard, with trailing 12 month revenue of about US$7.4 million and net income of roughly US$1.0 million, translating to EPS of US$0.06, while the latest half year print for H2 2025 showed revenue of US$3.6 million and EPS of US$0.02. Over the last reported halves, the company has seen total revenue move from US$2.8 million in H2 2024 to US$3.8 million in H1 2025 and US$3.6 million in H2 2025, with EPS of roughly US$0.04 in both H2...
NasdaqGS:LAES
NasdaqGS:LAESSemiconductor

SEALSQ (LAES) Heavy 1H FY 2025 US$20m Loss Reinforces Bearish Community Narratives

SEALSQ (LAES) just posted its FY 2025 first half numbers with revenue of roughly US$4.8 million and a basic EPS loss of US$0.17, against a trailing twelve month loss of US$0.38 per share on about US$11.0 million of revenue. Over the last three reported half year periods, revenue has moved between about US$4.8 million and US$6.2 million, while basic EPS losses ranged from US$0.17 to US$0.60. This has kept margins firmly in the red and put the focus squarely on how the business can turn growing...
NasdaqGM:PNBK
NasdaqGM:PNBKBanks

Patriot National Bancorp (PNBK) Quarterly Loss Narrows To US$0.02 EPS Challenging Persistent Bearish Narratives

Patriot National Bancorp (PNBK) just closed out FY 2025 with fourth quarter revenue of US$9.8 million and a basic EPS loss of US$0.02, alongside trailing twelve month revenue of US$28.1 million and a basic EPS loss of US$0.17. Over recent quarters the company has seen revenue move from US$4.7 million in Q2 2025 to US$7.6 million in Q3 2025 and then to US$9.8 million in Q4 2025. Quarterly basic EPS losses narrowed from US$0.21 in Q1 2025 to US$0.06 in Q2, US$0.03 in Q3 and US$0.02 in Q4...
NasdaqGS:VC
NasdaqGS:VCAuto Components

Is Visteon (VC) Rewriting Its Cockpit Electronics Story With Softer 2026 Guidance?

In recent days, Visteon reported mixed fourth-quarter results, with revenue exceeding expectations while earnings and full-year guidance, including softer 2026 revenue and EBITDA forecasts, fell short of analyst estimates. Analysts have largely maintained positive ratings despite trimming some expectations, highlighting investors’ focus on how Visteon balances growth in digital cockpit and connected car solutions with more cautious longer-term guidance. Next, we’ll examine how Visteon’s...
NasdaqCM:ANNA
NasdaqCM:ANNARenewable Energy

AleAnna (ANNA) Q3 Profit Of US$3.3 Million Tests Loss Making Narrative

AleAnna (NasdaqCM:ANNA) has just posted another quarter of rapid top line expansion, with Q3 FY 2025 revenue of about US$11.2 million and basic EPS of US$0.08, against a backdrop of very large revenue growth of 2,471.5% over the past year while remaining unprofitable on a trailing 12 month view. Over recent periods the company has seen revenue move from roughly US$0.6 million in Q3 FY 2024 to US$11.2 million in Q3 FY 2025, while trailing 12 month EPS across the last reported quarters stayed...
NYSE:RH
NYSE:RHSpecialty Retail

RH (RH) Earnings Rebound And Margin Improvement Challenge Cautious Leverage Narratives

RH (RH) has wrapped up FY 2026 with fourth quarter revenue of US$842.6 million and basic EPS of US$1.53, capping a twelve month run where EPS on a trailing basis reached US$6.65 on revenue of about US$3.4 billion alongside a 72.4% year over year earnings recovery after several years of declines. Over the past eight quarters, revenue has moved from US$812.4 million in Q4 FY 2025 to US$842.6 million in Q4 FY 2026. Over the same period, quarterly EPS has ranged between US$0.75 and US$2.76 and...
NYSE:CE
NYSE:CEChemicals

Celanese Shelf Registration Adds Flexibility While Valuation Appears Depressed

Celanese Corporation (NYSE:CE) has filed an omnibus shelf registration with regulators. The filing allows the company to offer common stock, preferred stock, and debt securities over time. This structure gives Celanese the ability to raise capital when market conditions and funding needs align. Celanese produces specialty materials and chemicals used across sectors such as automotive, construction, and consumer goods, so access to flexible funding can matter for large projects or potential...
NYSE:EFOR
NYSE:EFORIT

Quinnox Deal and Everforth Rebrand Could Be A Game Changer For ASGN (ASGN)

In its latest quarter, ASGN reported revenue and adjusted EBITDA margins ahead of expectations but missed EPS forecasts, while also outlining integration of the Quinnox acquisition and a rebranding to Everforth to consolidate its seven brands. This combination of earnings mixed with margin outperformance and a pivot toward higher-value consulting and unified branding could meaningfully reshape ASGN’s business mix and competitive positioning over time. We’ll now examine how ASGN’s Quinnox...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte HS Data Tests New Leadership And Povorcitinib Growth Potential

Incyte (NasdaqGS:INCY) released 54-week pivotal Phase 3 data from its STOP-HS program for povorcitinib in moderate to severe hidradenitis suppurativa (HS). The data show durable efficacy across multiple clinical response thresholds and improvements in patient quality of life at 54 weeks. Safety results were consistent over the long term, supporting the overall benefit risk profile of povorcitinib in HS. This is the first publication of long-term pivotal data for povorcitinib in HS ahead of...
NasdaqCM:ONCY
NasdaqCM:ONCYBiotechs

Oncolytics Biotech’s U.S. Move Resets Regulatory Path And Valuation Debate

Oncolytics Biotech (NasdaqCM:ONCY) has completed its domestication from Canada to the United States. The company has relocated its headquarters to San Diego, with the move now effective. Oncolytics Biotech is now classified as a U.S. domestic issuer under the U.S. regulatory framework. The domestication is intended to support operational efficiencies and access to U.S. capital markets. For you as an investor, this shift touches on both regulation and capital access. Oncolytics Biotech is an...
NYSEAM:KULR
NYSEAM:KULRElectrical

KULR Technology Group (KULR) Q4 Loss Of US$44.3 Million Tests Bullish Growth Narratives

KULR Technology Group (KULR) closed FY 2025 with fourth quarter revenue of US$2.9 million and a basic EPS loss of US$0.97, alongside a trailing twelve month EPS loss of US$1.56 on revenue of US$16.2 million. Over the last few quarters, the company has reported revenue between US$2.4 million and US$6.9 million per quarter, while quarterly EPS has ranged from a loss of US$0.54 to a gain of US$0.22. This leaves investors focusing on how quickly these top line changes might translate into...
NasdaqCM:FTLF
NasdaqCM:FTLFPersonal Products

FitLife Brands (FTLF) Margin Compression In FY 2025 Tests Bullish Growth Narratives

FitLife Brands (FTLF) has just closed out FY 2025 with fourth quarter revenue of US$25.9 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$81.5 million and EPS of US$0.68 that investors will be watching against the prior year’s figures. Over recent quarters the company has seen revenue move from US$15.0 million in Q4 FY 2024 to US$25.9 million in Q4 FY 2025, while quarterly EPS shifted from US$0.23 to US$0.17, setting the backdrop for the latest full year read on...
NasdaqGS:CHKP
NasdaqGS:CHKPSoftware

Check Point Software Technologies (CHKP) Margin Expansion To 38.8% Tests Bearish EPS Decline Narrative

Check Point Software Technologies (CHKP) closed out FY 2025 with fourth quarter revenue of US$744.9 million and basic EPS of US$2.85, while full year trailing EPS reached US$9.85 on revenue of US$2.7 billion and earnings grew 25% over the past 12 months. Over the last few reported periods, revenue has moved from US$703.7 million in Q4 2024 to US$744.9 million in Q4 2025, with quarterly basic EPS ranging from US$1.77 in Q1 2025 to US$3.34 in Q3 2025 and trailing net income rising from US$845.7...
NasdaqGS:DWSN
NasdaqGS:DWSNEnergy Services

Dawson Geophysical (DWSN) Returns To Quarterly Profit Challenging Volatility‑Focused Narratives

Dawson Geophysical (DWSN) closed out FY 2025 with fourth quarter revenue of US$26.9 million and basic EPS of US$0.02, alongside net income of US$0.6 million. This set a cleaner finish to a year where the trailing twelve month figures still show a loss of US$1.9 million on US$75.6 million of revenue and a basic EPS loss of US$0.06. Over recent quarters the company has seen quarterly revenue range from US$9.9 million to US$26.9 million, with EPS moving between a loss of US$0.08 and a profit of...
NasdaqGS:SIMO
NasdaqGS:SIMOSemiconductor

Silicon Motion Targets Auto Grade NAND To Balance AI And PC Cycles

Silicon Motion Technology (NasdaqGS:SIMO) is expanding its automotive grade NAND storage controller portfolio for connected and AI focused vehicles. The company is aligning products with automotive safety and cybersecurity standards such as AEC-Q100, ISO 26262, ISO 21434, and ASPICE Level 3. Its embedded storage solutions are being tailored for advanced driver-assistance systems and autonomous driving platforms. For readers following NasdaqGS:SIMO, this push into automotive storage sits on...
NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside

Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2. The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders. This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage. For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to...
NYSE:PM
NYSE:PMTobacco

Is Philip Morris International (PM) At An Attractive Price After Recent 11.5% Monthly Slide?

If you are wondering whether Philip Morris International is priced attractively at its current level, the key question is how its share price lines up with the value of its cash flows and assets. The stock last closed at US$165.34, with returns of 0.9% over 7 days, an 11.5% decline over 30 days, 3.1% year to date and 8.3% over the past year. These figures can change how investors think about both growth potential and risk. Recent news coverage has focused on Philip Morris International's...
NYSE:INR
NYSE:INROil and Gas

A Look At Infinity Natural Resources (INR) Valuation After Recent Share Price Volatility

Infinity Natural Resources (INR) has been drawing attention after recent trading swings, with the stock showing a mix of short term volatility and longer term moves that have left recent returns uneven for investors. See our latest analysis for Infinity Natural Resources. The recent pullback, with a 1 day share price return of a 4.55% decline to US$17.61, comes after a 19.55% 90 day share price return and a softer 1 year total shareholder return of a 4.81% decline. This suggests momentum has...
NasdaqGM:JFIN
NasdaqGM:JFINConsumer Finance

Does Jiayin Group’s (JFIN) Bigger Dividend And Buyback Hint At A Strategic Capital Shift?

Jiayin Group Inc. has reported its fourth-quarter and full-year 2025 results, showing quarterly revenue of CNY 1,090.2 million and net income of CNY 100.63 million, alongside full-year revenue of CNY 6,222.19 million and net income of CNY 1,535.74 million. Alongside these results, the company increased its dividend payout framework to target around 30% of prior-year net income and completed a share repurchase of 4,600,000 shares, equal to 8.6% of its share count, signaling a stronger focus...
NasdaqGS:WB
NasdaqGS:WBInteractive Media and Services

What Weibo (WB)'s Q4 Loss and Steady Dividend Decision Means For Shareholders

Weibo Corporation has reported its fourth-quarter and full-year 2025 results, with quarterly revenue rising to US$473.26 million but moving from net income to a net loss, while full-year revenue inched up to US$1.76 billion and net income increased to US$449.02 million. Alongside these results, the company’s board approved an annual cash dividend of US$0.61 per ordinary share or ADS for 2025, signaling a continued return of capital to shareholders despite the weaker fourth-quarter...
NYSE:VST
NYSE:VSTRenewable Energy

Vistra Secures Dual Investment Grade As Market Pullback Meets Valuation Upside

Vistra (NYSE:VST) has secured investment grade ratings from both Fitch and S&P. The dual ratings reflect stronger credit metrics and a balance sheet that supports a higher-quality credit profile. This credit upgrade may influence Vistra’s access to capital and its future financing terms. For shareholders watching NYSE:VST, the move to dual investment grade comes after a period of strong multi year share price gains alongside more recent pullbacks. The stock is trading at $150.33, with a 1...
NYSE:CNA
NYSE:CNAInsurance

CNA Financial’s FTSE All-World Removal Could Be A Game Changer For CNA Financial (CNA)

On 21 March 2026, CNA Financial Corporation was removed from the FTSE All-World Index (USD), meaning it no longer features in this broad global equity benchmark. This index removal can matter for investors because it may alter how index-tracking funds and benchmark-aware portfolios treat CNA Financial within diversified allocations. Next, we’ll examine how CNA Financial’s exclusion from the FTSE All-World Index could influence its previously positive, efficiency-focused investment...
NYSE:MKC
NYSE:MKCFood

McCormick (MKC) Margin Surge To 23.1% Challenges Bearish Profitability Narratives

McCormick (MKC) opened fiscal 2026 with Q1 revenue of US$1,873.9 million and basic EPS of US$3.78, set against trailing twelve month revenue of US$7.1 billion and EPS of US$6.12, where earnings over the last year were reported as up 109.4%. Over recent quarters the company has seen revenue move from US$1,605.5 million in Q1 2025 to US$1,850.4 million in Q4 2025 and then to US$1,873.9 million in Q1 2026. Quarterly EPS tracked from US$0.60 to roughly the mid US$0.80 range before the latest step...